MOUNTAIN VIEW, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal ...

Iridex (IRIX) announced the publication of a peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy in managing ...

Please provide your email address to receive an email when new articles are posted on . MONTEREY, Calif. — MicroPulse transscleral laser therapy delivered with a functionally and ergonomically revised ...

Part 2 recommendations address anesthesia, surgical technique, post-operative care, expected outcomes, settings adjustment, and enhancements and retreatments. 2 Part 1 of the consensus recommendations ...

Please provide your email address to receive an email when new articles are posted on . The European Glaucoma Society has accepted MicroPulse transscleral laser therapy into the latest edition of its ...

Led by Tomas M. Grippo, MD, of the Grippo Glaucoma & Cataract Center (Buenos Aires, Argentina), the study provides the first quantitative computer model comparing the thermal tissue effects of ...

IRIDEX Corporation (Nasdaq: IRIX) today announced that it will debut Cyclo G6, the Company's first laser platform dedicated to the treatment of glaucoma, at this year's annual congress of the American ...